Medtronic Cardiovascular — Selling, general, and administrative expense decreased by 1.2% to $1.13B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.8%, from $1.01B to $1.13B. This is a positive signal — lower values indicate better performance for this metric.
Lower expenses relative to sales indicate high operational leverage, while rising expenses may signal aggressive market expansion or inefficiency.
This includes all operating expenses for the cardiovascular segment related to sales, marketing, and general administrat...
Comparable to SG&A expenses in the cardiovascular divisions of global medical device competitors.
mdt_segment_cardiovascular_selling_general_and_administrative_expense| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $663.25M | $663.25M | $663.25M | $663.25M | $978.00M | $1.02B | $1.01B | $1.19B | $1.06B | $1.14B | $1.13B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +47.5% | +4.4% | -1.1% | +18.0% | -11.1% | +7.8% | -1.2% |
| YoY Change | — | — | — | — | +47.5% | +53.9% | — | — | +8.4% | +11.9% | +11.8% |